From Bench to bedside and back again-emerging opportunities

Christopher Buckley, Barry Bresnihan

Research output: Contribution to journalArticlepeer-review

10 Downloads (Pure)


We believe that an exciting new era of innovative therapeutic advancement has already begun. Patients with severe chronic rheumatic diseases can realistically entertain the expectation of substantial symptomatic improvement, or even of cure. The excitement of both scientists and clinicians is highlighted in this edition of Best Practice and Research Clinical Rheumatology. The proof of principle that targeting cytokines, such as tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β), with biological reagents may lead to spectacular biological outcomes has led us to believe that some diseases might even be cured.
Original languageEnglish
Pages (from-to)827-828
Number of pages2
JournalBest Practice and Research: Clinical Rheumatology
Issue number5
Publication statusPublished - Oct 2006


Dive into the research topics of 'From Bench to bedside and back again-emerging opportunities'. Together they form a unique fingerprint.

Cite this